axiVEND has signed a distribution agreement with Parallex BioAssays, to distribute the SnapChip, aka Chip2Chip technology, a multiplex assay platform with no detection cross-reactivity problems, for North and South America markets.

The SnapChip is a simple approach to multiplexing that eliminates non-specific cross reactivity readouts during the detection step of a sandwich ELISA. Eliminating the cross-reaction problem of multiplex ELISAs can bring about significant time savings in the early development of a multiplex test. The platform is suitable to reliably assess a number of proteins without the added noise from non- selective detection reagents.

"This cross-reaction-free platform offers high quality results while permitting rapid, flexible and customized multiplexed immunoassay development that will help accelerate academic and industrial research," said Sebastien Bergeron, Parallex CEO. "We are excited about our collaboration with axiVEND whose wide network will help realize the best development potential for our innovative platform."

"Beyond the SnapChip's innovative solution to multiplex assay development, axiVEND's synergistic portfolio promises to bring about a full solution to assay developers," said Claude Dufresne, axiVEND CEO. "We provide the full range of equipment needed to perform this development in-house, or as a service, and still enable you to perform your assays in your lab. Combining the SnapChip platform with optimal immobilization, spotting and reader offerings will make the approach excel in providing timely and superior multiplex assay results."

About Parallex BioAssays

Parallex BioAssays was founded in 2015 in Montreal, Canada, with a mission to offer innovative and customizable solutions to accelerate academic and industrial research.

Parallex has developed a new microarray format called the SnapChip, that has made...

To continue reading